Advertisement

Pharmaka mit Wirkung auf den Verdauungstrakt

  • E. Oberdisse
Chapter
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Bei einer Hypo- oder Achlorhydrie kann u.U. die Zufuhr von Säure notwendig werden, weil der optimale pH-Wert von etwa 2 für die Aktivierung von Pepsin nicht mehr erreicht wird. Bei der Substitution mit Säuren ergibt sich jedoch die Schwierigkeit, daß die üblicherweise verwendeten Mengen bei weitem nicht ausreichen, weil durch den Mageninhalt eine starke Pufferung stattfindet. Der Wert einer „üblichen“ Säuresubstitution bleibt daher zweifelhaft.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Avery GS, Davies EF, Brogden RN (1972) Lactulose: A review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action in portal systemic encephalopathy. Drugs 4:7–48PubMedCrossRefGoogle Scholar
  2. Awouters F, Niemeggers CJE, Janssen PAJ (1983) Pharmacology of antidiarrheal drugs. Annu Rev Pharmacol Toxicol 23:279–301PubMedCrossRefGoogle Scholar
  3. Bertaccini G (ed) (1982) Mediators and drugs in gastrointestinal motility I and II. Handbook of experimental pharmacology, vol 59/I, 59/II. Springer, Berlin Heidelberg New YorkGoogle Scholar
  4. Bianchi-Porro G, Parente F (1991) „Difficult“ duodenal ulcer patients: Clinical and therapeutic problems. Dig Dis 9:219–228PubMedCrossRefGoogle Scholar
  5. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Ranitidine: A review of its pharmacological and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 24:267–303PubMedCrossRefGoogle Scholar
  6. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone: A review of its pharmacological activity, pharmacokinetics, and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24:360–400PubMedCrossRefGoogle Scholar
  7. Collen MJ, Benjamin SB (eds) (1991) Pharmacology of peptic ulcer disease, In: Handbook of experimental pharmacology, vol 99. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  8. Cover TL, Blaser MJ (1992) Helicobacter pylori and gastroduodenal disease. Annu Rev Med 43:135–145PubMedCrossRefGoogle Scholar
  9. Czaky TZ (ed) (1984) Pharmacology of intestinal permeation I and II. Handbook of experimental pharmacology, vol 70/I, 70/II. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  10. Groß V, Schölmerich J (1993) Morbus Crohn und Colitis ulcerosa, Fortschritte in der medikamentösen Therapie. Dtsch Ärztebl 90:B-2335–B-2341Google Scholar
  11. Guerrant RL, Bobak DA (1991) Bacterial and protozoal gastroenteritis. N Engl J Med 325:327–340PubMedCrossRefGoogle Scholar
  12. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romanhiewicz JA, Heel RC (1983) Metoclopramide: An updated review of its pharmacological properties and clinical use. Drugs 25:451–494PubMedCrossRefGoogle Scholar
  13. Hersey SJ, Sachs G (1995) Gastric acid secretion. Physiol Rev 75:155–189PubMedGoogle Scholar
  14. Hixson LJ, Kelley CL, Jones WN, Tuohy CD (1992) Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med 152:726–732PubMedCrossRefGoogle Scholar
  15. Lanzini A, Northfield TC (1994) Pharmacological treatment of gallstones: Practical guidelines. Drugs 47:458–470PubMedCrossRefGoogle Scholar
  16. Lauritsen K, Laursen LS, Rask-Madsen J (1990) Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I and II). Clin Pharmacokinet 19:11–31PubMedCrossRefGoogle Scholar
  17. Lauritsen K, Laursen LS, Rask-Madsen J (1990) Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I and II). Clin Pharmacokinet 19:94–125PubMedCrossRefGoogle Scholar
  18. Leopolder-Ochsendorf A, Holtermüller K-H (1985) Nebenwirkungen der Antazida. Dtsch Med Wochenschr 110:1216–1219PubMedCrossRefGoogle Scholar
  19. Manara L, Bianchetti A (1985) The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 25:249–273PubMedCrossRefGoogle Scholar
  20. McCarthy DM (1991) Sucralfate. N Engl J Med 325:1017–1025PubMedCrossRefGoogle Scholar
  21. Murer H, Burckhardt G (1983) Membrane transport of anions across epithelia of mammalian small intestine and kidney proximal tubule. Rev Physiol Biochem Pharmacol 96:1–51PubMedCrossRefGoogle Scholar
  22. Nash J, Lambert L, Deakin M (1994) Histamine H2-receptor antagonists in peptic ulcer disease: Evidence for a prophylactic use. Drugs 47:862–871PubMedCrossRefGoogle Scholar
  23. NN (1980) Laxanzien — pharmakologische Wirkungen, Nebenwirkungen und kritischer Gebrauch. Arzneimittelbrief 14:85–89Google Scholar
  24. NN (1981) Motilitätswirksame Medikamente zur Behandlung gastrointestinaler Funktionsstörungen. Arzneimittelbrief 15:101–105Google Scholar
  25. Okhuysen PC, Ericsson CD (1992) Travellers’ diarrhea, prevention and treatment. Med Clin North Am 76:1357–1373PubMedGoogle Scholar
  26. Pope AJ, Parsons ME (1993) Reversible inhibitors of the gastric H+/K+-transporting ATPase: A new class of anti-secretory agents. Trends Pharmacol Sci 14:323–325PubMedCrossRefGoogle Scholar
  27. Protzer U, Holtermüller KH (1993) Omeprazol, Pharmakologie und therapeutische Wirksamkeit. Dtsch Med Wochenschr 118:230–239PubMedCrossRefGoogle Scholar
  28. Raufman J-P (1992) Gastric chief cells: Receptors and signaltransduction mechanisms. Gastroenterology 102:699–710PubMedGoogle Scholar
  29. Rösch W (1993) Diagnose und Therapie der funktionellen Dyspepsie. Dtsch Med Wochenschr 118:1729–1732PubMedCrossRefGoogle Scholar
  30. Ruoff H-J, Fladung B, Demol P, Weihrauch TR (1991) Gastrointestinal receptors and drugs in motility disorders. Digestion 48:1–17PubMedCrossRefGoogle Scholar
  31. Sachs G, Shin JM, Briving C, Wallmark B, Gersey S (1995) The pharmacology of the gastric acid pump: The H+/K+ ATPase. Annu Rev Pharmacol 35:277–305CrossRefGoogle Scholar
  32. Sack DA (1982) Treatment of acute diarrhoea with oral rehydratation solution. Drugs 23:150–157PubMedCrossRefGoogle Scholar
  33. Simon B, Müller P (1991) Ondansetron. Arzneimitteltherapie 9:97–99Google Scholar
  34. Slomiany BL, Piotrowsi J, Tamura S, Slomiany A (1991) Enhancement of the protective qualities of gastric mucus by sucralfate: Role of phosphoinositides. Am J Med 91 [Suppl 2A]:30S–36SPubMedCrossRefGoogle Scholar
  35. Walsh JH, Peterson WL (1995) The treatment of Helicobacter pylori in the management of peptic ulcer disease. N Engl J Med 333:984–991PubMedCrossRefGoogle Scholar
  36. Walt RP (1992) Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 327:1575–1580PubMedCrossRefGoogle Scholar
  37. Wanitschke R (1985) Leitsymptom Diarrhö. Dtsch Ärztebl 82:563–573Google Scholar
  38. Wiseman LR, Faulds D (1994) Cisapride: An updated review of its pharmacology and therapeutic efficacy as a pro-kinetic agent in gastrointestinal motility disorders. Drugs 47:116–152PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Oberdisse

There are no affiliations available

Personalised recommendations